Highly Potent Antisense Oligonucleotides Locked Nucleic Acid Gapmers Targeting the SARS-CoV-2 RNA Genome

Area of Science:

• Virology
• Molecular Biology
• Drug Discovery

Background:

• The ongoing pandemic caused by SARS-CoV-2 highlights the need for diverse therapeutic strategies beyond vaccines.
• Current treatments aim to reduce disease severity, but novel compounds are required for severely infected individuals and transmission prevention.
• Developing a robust antiviral arsenal is crucial for managing current and future coronavirus threats.

Purpose of the Study:

• To investigate the potential of antisense oligonucleotides (ASOs) as a therapeutic strategy against SARS-CoV-2.
• To evaluate the efficacy of locked nucleic acid (LNA) gapmers in targeting the SARS-CoV-2 RNA genome.
• To assess the reduction of intracellular viral load using ASO-based therapies.

Main Methods:

• Design and selection of specific antisense oligonucleotides (ASOs) targeting the SARS-CoV-2 genome.
• Utilizing locked nucleic acid (LNA) gapmer technology for enhanced stability and binding affinity.
• In vitro testing to quantify the reduction in intracellular viral load in infected cells.

Main Results:

• Selected LNA gapmers demonstrated significant antiviral activity against SARS-CoV-2 in vitro.
• Intracellular viral load was reduced by up to 96% using the developed ASO compounds.
• The study provides proof-of-concept for ASO-based targeting of the viral RNA genome.

Conclusions:

• The developed ASOs represent a promising therapeutic approach for COVID-19.
• Further development of these ASOs is warranted for potential use as antiviral agents.
• This strategy offers a potential new tool for controlling SARS-CoV-2 and emerging coronavirus threats.